Company news
Orchestra Biomed Holdings, Inc. (NASDAQ:OBIO) news
Orchestra Biomed Holdings, Inc. news releases on 6ix. Latest, Aug 12, 2024: Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides…
Press releases — page 2
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 11, 2024
Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
July 29, 2024
Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
June 3, 2024
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
May 21, 2024
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
May 12, 2024
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
April 29, 2024
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
April 29, 2024
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
March 26, 2024
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
March 25, 2024
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
March 12, 2024
Orchestra BioMed to Participate in Upcoming Investor Conferences
March 6, 2024
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
March 5, 2024
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
February 25, 2024
Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients
January 7, 2024
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
November 12, 2023
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
September 18, 2023
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
August 9, 2023
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
August 7, 2023
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
June 25, 2023
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
June 6, 2023
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference
May 31, 2023
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023
February 23, 2023
Orchestra BioMed™ Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crossover Extension Study of BackBeat CNT™ at TCT 2022
September 19, 2022
Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2
July 4, 2022